Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COMFORT: IRX-101 vs Povidone-Iodine for Post-Intravitreal Pain
NCT05750589Phase 3Not yet recruiting
- Sponsor
- iRenix Medical, Inc.
- Start
- Sep 2026
- Primary completion
- Jan 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of IRX-101 in corneal epitheliopathy (2 arms), sponsored by iRenix Medical, Inc. Primary endpoint: Assessment of post-intravitreal injection eye pain. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
IRX-101
03
Conditions
corneal epitheliopathy
Beyond the preview
Go deeper on NCT05750589.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05750589.